- Healthy male or female subjects aged 21 to 55 years
- Healthy is defined as no clinical relevant abnormalities identified by a detailed
medical history, full physical examination including blood pressure and pulse rate
measurement, 12-lead ECG and clinical laboratory tests
- Willing to use acceptable methods of contraception as outlined in the study protocol
- Body mass index between 18 to 30 kg/m2
- Subjects who are willing and able to comply with the scheduled visits, treatment plan
and other study procedures
- Subjects with evidence or history of clinically significant disease
- Pregnant or nursing females
- Females of childbearing potential who are unwilling or unable to use an acceptable
method of nonhormonal contraception from at least 14 days prior to the first dose
until day 15 of period 4
- Subjects with conditions possibly affecting drug absorption (eg gastrectomy)
- A positive approved immunoassay/ELISA blood test for TB
- Subjects with a history of regular alcohol consumption exceeding 14 drinks/week for
females or 21 drinks/week for men
- Subjects who have use prescription or nonprescription drugs, vitamins and/or dietary
supplements within 7 days or 5 half-lives (whichever is longer) prior to the first
dose of study medication
- Subjects who have been administered medications capable of inducing hepatic enzyme
metabolism (eg barbiturates, rifampin, carbamazepine, phenytoin or primidone) within
14 days (or 5 half-lives of the inducing agent, whichever is longer) of day 1 or
within 28 days of administration of St John's wort